Jury Finds for Takeda in Diabetes Drug Case
Takeda Pharmaceuticals U.S.A. announced that in the case of Whitlatch v. Takeda the jury found in favor of Takeda. The trial began on April 21 in the Circuit Court of Cook County, Illinois, before Judge Deborah Dooling and is the fifth ACTOS (pioglitazone HCl) case to reach trial.
"We empathize with the Whitlatch family but agree with the verdict," said Kenneth D. Greisman, senior vice president, general counsel, Takeda Pharmaceuticals U.S.A., Inc. "Takeda is confident in the therapeutic benefits of ACTOS and its importance as a treatment for type 2 diabetes."
Takeda prevailed in three previous ACTOS trials and is challenging the outcome of the fourth.
"Patient safety is a critical priority for Takeda," said Greisman. "We believe that we have acted responsibly with regard to ACTOS and plan to vigorously defend the company against future lawsuits of this type."